Der nette waikiki5800 war so nett und hat eine Mail an den CEO von Clinuvel $CUV (-0,59 %) geschickt und eine Antwort bekommen:

We will issue a video address to shareholders next week to answer some questions.

First, our mandate was to build a profitable company against all odds of using technology that had failed for three decades. This strategy led to a financially robust company with A$195 million in cash and growing.

Second, a share price does not define our teams or success, as a matter of fact the Company was less advanced and had less prospect and hardly any cash when it was valued at A$44 per share.

Third, shareholders should analyze that the largest shareholder of the company is the CEO, and price would affect him most, but he is. It worried nor selling.

Fourth, biotech companies go through highs and lows based on sentiment only, not real economics.

Fifth, Clinuvel belongs to a handful of companies worldwide posting 8 years profits, we intend to continue this trend providing shareholders confidence that CUV is a viable business.

Sixth cash is being used to expand vitiligo, ACTH programs.

Seventh, shareholders need to do their own analyses of my management team and resilience to overcome setbacks, a low share price is the least of our daily business problems.

Dann warten wir mal, was da nächste Woche kommt.